Time-resolved role of P2X4 and P2X7 during CD8+ T cell activation

Standard

Time-resolved role of P2X4 and P2X7 during CD8+ T cell activation. / Brock, Valerie J; Lory, Niels Christian; Möckl, Franziska; Birus, Melina; Stähler, Tobias; Woelk, Lena-Marie; Jaeckstein, Michelle; Heeren, Joerg; Koch-Nolte, Friedrich; Rissiek, Björn; Mittrücker, Hans-Willi; Guse, Andreas H; Werner, René; Diercks, Björn-Philipp.

In: FRONT IMMUNOL, Vol. 15, 2024, p. 1258119.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{594701c86acc4e0d9ecfdbc6ba1e1f20,
title = "Time-resolved role of P2X4 and P2X7 during CD8+ T cell activation",
abstract = "CD8+ T cells are a crucial part of the adaptive immune system, responsible for combating intracellular pathogens and tumor cells. The initial activation of T cells involves the formation of highly dynamic Ca2+ microdomains. Recently, purinergic signaling was shown to be involved in the formation of the initial Ca2+ microdomains in CD4+ T cells. In this study, the role of purinergic cation channels, particularly P2X4 and P2X7, in CD8+ T cell signaling from initial events to downstream responses was investigated, focusing on various aspects of T cell activation, including Ca2+ microdomains, global Ca2+ responses, NFAT-1 translocation, cytokine expression, and proliferation. While Ca2+ microdomain formation was significantly reduced in the first milliseconds to seconds in CD8+ T cells lacking P2X4 and P2X7 channels, global Ca2+ responses over minutes were comparable between wild-type (WT) and knockout cells. However, the onset velocity was reduced in P2X4-deficient cells, and P2X4, as well as P2X7-deficient cells, exhibited a delayed response to reach a certain level of free cytosolic Ca2+ concentration ([Ca2+]i). NFAT-1 translocation, a crucial transcription factor in T cell activation, was also impaired in CD8+ T cells lacking P2X4 and P2X7. In addition, the expression of IFN-γ, a major pro-inflammatory cytokine produced by activated CD8+ T cells, and Nur77, a negative regulator of T cell activation, was significantly reduced 18h post-stimulation in the knockout cells. In line, the proliferation of T cells after 3 days was also impaired in the absence of P2X4 and P2X7 channels. In summary, the study demonstrates that purinergic signaling through P2X4 and P2X7 enhances initial Ca2+ events during CD8+ T cell activation and plays a crucial role in regulating downstream responses, including NFAT-1 translocation, cytokine expression, and proliferation on multiple timescales. These findings suggest that targeting purinergic signaling pathways may offer potential therapeutic interventions.",
author = "Brock, {Valerie J} and Lory, {Niels Christian} and Franziska M{\"o}ckl and Melina Birus and Tobias St{\"a}hler and Lena-Marie Woelk and Michelle Jaeckstein and Joerg Heeren and Friedrich Koch-Nolte and Bj{\"o}rn Rissiek and Hans-Willi Mittr{\"u}cker and Guse, {Andreas H} and Ren{\'e} Werner and Bj{\"o}rn-Philipp Diercks",
note = "Copyright {\textcopyright} 2024 Brock, Lory, M{\"o}ckl, Birus, St{\"a}hler, Woelk, Jaeckstein, Heeren, Koch-Nolte, Rissiek, Mittr{\"u}cker, Guse, Werner and Diercks.",
year = "2024",
doi = "10.3389/fimmu.2024.1258119",
language = "English",
volume = "15",
pages = "1258119",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Time-resolved role of P2X4 and P2X7 during CD8+ T cell activation

AU - Brock, Valerie J

AU - Lory, Niels Christian

AU - Möckl, Franziska

AU - Birus, Melina

AU - Stähler, Tobias

AU - Woelk, Lena-Marie

AU - Jaeckstein, Michelle

AU - Heeren, Joerg

AU - Koch-Nolte, Friedrich

AU - Rissiek, Björn

AU - Mittrücker, Hans-Willi

AU - Guse, Andreas H

AU - Werner, René

AU - Diercks, Björn-Philipp

N1 - Copyright © 2024 Brock, Lory, Möckl, Birus, Stähler, Woelk, Jaeckstein, Heeren, Koch-Nolte, Rissiek, Mittrücker, Guse, Werner and Diercks.

PY - 2024

Y1 - 2024

N2 - CD8+ T cells are a crucial part of the adaptive immune system, responsible for combating intracellular pathogens and tumor cells. The initial activation of T cells involves the formation of highly dynamic Ca2+ microdomains. Recently, purinergic signaling was shown to be involved in the formation of the initial Ca2+ microdomains in CD4+ T cells. In this study, the role of purinergic cation channels, particularly P2X4 and P2X7, in CD8+ T cell signaling from initial events to downstream responses was investigated, focusing on various aspects of T cell activation, including Ca2+ microdomains, global Ca2+ responses, NFAT-1 translocation, cytokine expression, and proliferation. While Ca2+ microdomain formation was significantly reduced in the first milliseconds to seconds in CD8+ T cells lacking P2X4 and P2X7 channels, global Ca2+ responses over minutes were comparable between wild-type (WT) and knockout cells. However, the onset velocity was reduced in P2X4-deficient cells, and P2X4, as well as P2X7-deficient cells, exhibited a delayed response to reach a certain level of free cytosolic Ca2+ concentration ([Ca2+]i). NFAT-1 translocation, a crucial transcription factor in T cell activation, was also impaired in CD8+ T cells lacking P2X4 and P2X7. In addition, the expression of IFN-γ, a major pro-inflammatory cytokine produced by activated CD8+ T cells, and Nur77, a negative regulator of T cell activation, was significantly reduced 18h post-stimulation in the knockout cells. In line, the proliferation of T cells after 3 days was also impaired in the absence of P2X4 and P2X7 channels. In summary, the study demonstrates that purinergic signaling through P2X4 and P2X7 enhances initial Ca2+ events during CD8+ T cell activation and plays a crucial role in regulating downstream responses, including NFAT-1 translocation, cytokine expression, and proliferation on multiple timescales. These findings suggest that targeting purinergic signaling pathways may offer potential therapeutic interventions.

AB - CD8+ T cells are a crucial part of the adaptive immune system, responsible for combating intracellular pathogens and tumor cells. The initial activation of T cells involves the formation of highly dynamic Ca2+ microdomains. Recently, purinergic signaling was shown to be involved in the formation of the initial Ca2+ microdomains in CD4+ T cells. In this study, the role of purinergic cation channels, particularly P2X4 and P2X7, in CD8+ T cell signaling from initial events to downstream responses was investigated, focusing on various aspects of T cell activation, including Ca2+ microdomains, global Ca2+ responses, NFAT-1 translocation, cytokine expression, and proliferation. While Ca2+ microdomain formation was significantly reduced in the first milliseconds to seconds in CD8+ T cells lacking P2X4 and P2X7 channels, global Ca2+ responses over minutes were comparable between wild-type (WT) and knockout cells. However, the onset velocity was reduced in P2X4-deficient cells, and P2X4, as well as P2X7-deficient cells, exhibited a delayed response to reach a certain level of free cytosolic Ca2+ concentration ([Ca2+]i). NFAT-1 translocation, a crucial transcription factor in T cell activation, was also impaired in CD8+ T cells lacking P2X4 and P2X7. In addition, the expression of IFN-γ, a major pro-inflammatory cytokine produced by activated CD8+ T cells, and Nur77, a negative regulator of T cell activation, was significantly reduced 18h post-stimulation in the knockout cells. In line, the proliferation of T cells after 3 days was also impaired in the absence of P2X4 and P2X7 channels. In summary, the study demonstrates that purinergic signaling through P2X4 and P2X7 enhances initial Ca2+ events during CD8+ T cell activation and plays a crucial role in regulating downstream responses, including NFAT-1 translocation, cytokine expression, and proliferation on multiple timescales. These findings suggest that targeting purinergic signaling pathways may offer potential therapeutic interventions.

U2 - 10.3389/fimmu.2024.1258119

DO - 10.3389/fimmu.2024.1258119

M3 - SCORING: Journal article

C2 - 38426095

VL - 15

SP - 1258119

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -